Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis
M Miravitlles, F Kruesmann… - European …, 2012 - Eur Respiratory Soc
We examined the correlation between sputum colour and the presence of potentially pathogenic
bacteria in acute exacerbations of chronic bronchitis (AECBs). Data were pooled from …
bacteria in acute exacerbations of chronic bronchitis (AECBs). Data were pooled from …
[HTML][HTML] Moxifloxacin safety: an analysis of 14 years of clinical data
PM Tulkens, P Arvis, F Kruesmann - Drugs in R&D, 2012 - Springer
Background Moxifloxacin, a fluoroquinolone antibiotic, is used for the treatment of respiratory
tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is …
tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is …
Update on the cardiac safety of moxifloxacin
W Haverkamp, F Kruesmann, A Fritsch… - Current drug …, 2012 - ingentaconnect.com
Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in
a large patient population from Phase II–IV randomized active-controlled clinical trials. …
a large patient population from Phase II–IV randomized active-controlled clinical trials. …
Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials
…, JM Tellado, G Weiss, J Alder, F Kruesmann… - Surgical …, 2014 - liebertpub.com
Background: Secondary peritonitis is an advanced form of complicated intra-abdominal
infection (cIAI) requiring hospitalization, surgical source control, and empiric antibiotic therapy …
infection (cIAI) requiring hospitalization, surgical source control, and empiric antibiotic therapy …
[PDF][PDF] Introduction and Objectives
PM Tulkens, P Arvis, F Kruesmann - Citeseer
Results 1. Population (by route of administration, indication and risk factors) 1. Population
(by route of administration, indication and risk factors)
(by route of administration, indication and risk factors)
Comparative efficacy of oral and sequential intravenous/oral moxifloxacin in the treatment of community acquired pneumonia (CAP) in the very elderly (age>= 75 …
A Anzueto, D Haverstock, F Kruesmann, S Choudhri - Chest, 2005 - journal.chestnet.org
PURPOSE: To evaluate the efficacy and safety of sequential IV/PO and PO moxifloxacin (MXF)
versus that of comparator (COMP) antibiotics in very elderly (≥ 75 years old) patients …
versus that of comparator (COMP) antibiotics in very elderly (≥ 75 years old) patients …
[HTML][HTML] No relationship between biopsy sites near the main testicular vessels or rete testis and successful sperm retrieval using conventional or microdissection …
…, K Fiedler, I Von Hertwig, G Krüsmann… - Asian Journal of …, 2013 - ncbi.nlm.nih.gov
In 220 consecutive patients with non-obstructive azoospermia, sperm retrieval was
attempted by a combination of conventional and microdissection testicular sperm extraction (TESE). …
attempted by a combination of conventional and microdissection testicular sperm extraction (TESE). …
[PDF][PDF] Balancing parenting and work: Understanding women's work orientations and working realities, and pressures of balancing parenting and work
M Kruesmann, E Hsu, K Vella… - Eighth …, 2003 - melbourneinstitute.unimelb.edu.au
The opinions, comments and/or analysis expressed in this paper are those of the author
and do not represent the views of the Minister for Family and Community Services or the …
and do not represent the views of the Minister for Family and Community Services or the …
[PDF][PDF] BALANCING PARENTING AND WORK: Understanding women's work orientations and working realities, and pressures of
M Kruesmann, E Hsu, K Vella, F Jones - researchgate.net
The opinions, comments and/or analysis expressed in this paper are those of the author
and do not represent the views of the Minister for Family and Community Services or the …
and do not represent the views of the Minister for Family and Community Services or the …
[CITATION][C] Drugs in Research and Development (Drugs in R&D) DRD-S-12-00850–In press
PM Tulkens, P Arvis, F Kruesmann